Biotechnology
featured
Shares of Pandora are up after the company reported earnings, reports CNBC's Seema Mody. And there are reports a deal between Valeant Pharmaceuticals and Bausch & Lomb could be completed as early as next week.
» Read MoreMore
-
Shares of Pandora are up after the company reported earnings, reports CNBC's Seema Mody. And there are reports a deal between Valeant Pharmaceuticals and Bausch & Lomb could be completed as early as next week.
-
NEW YORK, May 22- Little known biotechnology company Merrimack Pharmaceuticals Inc has quietly built a large pipeline of experimental cancer treatments that it aims to deliver at a fraction of the cost spent by larger rivals. Medicare system contending with new cancer treatments that can exceed $100,000 per patient.
-
Following is Cramer's homework. And he's concerned about a few of the stocks he's just researched.
-
Amgen's stock fell sharply in after-hours trading after it reported sales that fell short of Wall Street's expectations.
-
Mark Lehmann, JMP Securities president, provides investment strategies that include a biotech company with a promising drug to fight a rare form of Leukemia.
-
CHICAGO, April 17- In a move to shore up its lead in Alzheimer's diagnostics, Eli Lilly and Co on Wednesday said it will acquire two imaging agents from Siemens designed to light up brain deposits of tau, an Alzheimer's protein linked with cell death. Terms of the deal with the conglomerate's Siemens Medical Solutions USA unit were not disclosed.
-
Road trip! Road trip! In the second stop, CNBC's Brian Sullivan reports on the biotech boom in San Diego.
-
San Diego Mayor Bob Filner (D) discusses the growing sectors in the city, rising home prices, and the burgeoning biotech industry.
-
CNBC's Jane Wells reports on business in San Diego, how the city has come back from the brink of bankruptcy, and the diversity of the economy. Just the same, taxes are among the highest in the country.
-
San Diego has the 2nd largest biotech industry in the U.S. CNBC's Brian Sullivan is there to check it out.
-
Biotech has returned 20 percent for investors this year. Biogen IDEC CEO George Scangos, discusses the recent FDA approval of his company's drug, which is its first pill for multiple sclerosis.
-
*Research sheds light on breast, prostate, ovarian cancer. LONDON, March 27- New research has nearly doubled the number of genetic variations implicated in breast, prostate and ovarian cancer, offering fresh avenues for screening at-risk patients and, potentially, developing better drugs.
-
It is the 95th consecutive trading session in which Apple shares trade below its 50-day moving average, reports CNBC's Seema Mody.
-
CNBC's Seema Mody reports BlackBerry is up today after reports that BBerry 10 is selling faster than expected.
-
Feb 15- A 75- year-old Indiana grain farmer will take on global seed giant Monsanto Co at the U.S. Supreme Court next week in a patent battle that could have ramifications for the biotechnology industry and possibly the future of food production.
-
*U.S. Supreme Court to consider same issue in April. CANBERRA, Feb 15- An Australian court ruled on Friday that two technology companies could hold a patent on genetic material related to cancer, in a case similar to one before the U.S. Supreme Court that has implications for gene-based medicine worldwide.
-
*KDDI lifts full-year earnings forecast. *HSBC cuts Japan rating, BNP sees index rising to 13,000.
-
An internal analysis conducted by Johnson & Johnson in 2011 estimated that the all-metal device would fail within five years in nearly 40 percent of patients who received it, newly disclosed court records show.
-
Biotech stocks are outperforming the major indices, and are up 3 percent over the past week. CNBC's Seema Mody is tracking which stocks are trending on Twitter.
-
Eli Lilly will be "very challenged" by the loss of exclusivity on several blockbuster drugs, CEO John Lechleiter told CNBC on Tuesday, but added the company can manage its growth in response.